Heart Disease Therapy
Sarpogrelate possesses cardiovascular and renal clinical potential
Published in Medical Letter on the CDC and FDA, October 24th, 2004
"Sarpogrelate is a selective 5-hydroxytryptamine receptor subtype 2A (5-HT2A ) antagonist. It is metabolized to racemic M-1 and both enantiomers of M-1 are also antagonists of 5-HT2A receptors. Sarpogrelate inhibits responses to 5-HT mediated by 5-HT2A receptors such as platelet aggregation, vasoconstriction, and vascular smooth muscle proliferation. There is no information available on the pharmacokinetics of sarpogrelate," a scientist in New Zealand reports.
"Sarpogrelate is efficacious in animal models of thrombosis, coronary artery spasm,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Aspergillus
Assay to differentiate Aspergillus from other yeasts developed - Brucella
16S rRNA gene sequencing used for rapid identification of Brucella - Food-Borne Illness
Salmonella and E. coli may grow in oranges meant for juice - Nocardia
PCR method developed for rapid identification of Nocardia farcinica - Virology
Coliphage PR772 evaluated for use in virus filter performance testing - AIDS/HIV Diagnosis
Rapid and conventional testing methods for HIV screening compared - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
